Acute Ischemic Stroke Clinical Trial
— SERICT-AISOfficial title:
Safety and Effectiveness of Remote Ischemic Conditioning Combined With Intravenous Thrombolysis in Treating Acute Ischemic Stroke
| NCT number | NCT04027621 |
| Other study ID # | SERICT-AIS |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | July 1, 2019 |
| Est. completion date | July 20, 2020 |
| Verified date | June 2022 |
| Source | The First Hospital of Jilin University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning combined with intravenous thrombolysis in treating acute ischemic stroke.
| Status | Completed |
| Enrollment | 50 |
| Est. completion date | July 20, 2020 |
| Est. primary completion date | July 1, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility | Inclusion Criteria: - 1) Age=18 years, < 80 years, regardless of sex; - 2) Patients with clinically definite diagnosis of acute ischemic stroke and undergo intravenous thrombolysis; - 3) Baseline NIHSS >= 5, and <= 25; - 4) Baseline GCS =8; - 5) Signed and dated informed consent is obtained Exclusion Criteria: - 1) Patients who undergo endovascular treatment; - 2) mRS = 2 before the onset of the disease; - 3) Double upper limbs or lower limbs paralysis was found in this case; - 4) Active bleeding of organs within 6 months of admission or current, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage and so on; - 5) Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumor and other diseases involving the brain; - 6) Concurrent use of anticoagulation drugs including Warfarin, dabigatran, rivaroxaban; - 7) Severe organ dysfunction or failure; - 8) Patients suffering from severe hematological diseases or severe coagulation disorder dysfunction - 9) Those who have a history of severe trauma or had major surgery within 6 months prior to admission; - 10) Those who have a history of atrial fibrillation; - 11) The patients who have the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb#Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; - 12) Pregnant or lactating women; - 13) Previous remote ischemic conditioning therapy or similar treatment; - 14) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons; - 15) Severe hepatic and renal dysfunction; - 16) Unwilling to be followed up or treated for poor compliance; - 17) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission; - 18) Other conditions that the researchers think are not suitable for the group. |
| Country | Name | City | State |
|---|---|---|---|
| China | The First Hospital of Jilin University | Chang chun | Jilin |
| Lead Sponsor | Collaborator |
|---|---|
| Yi Yang |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Changes of hematological indicators | Hematological samples are collected at right before thrombolysis and 24 hours after thrombolysis, and changes of hematological indicators related to hemorrhagic transformation (such as Axl, ANGPTL4) are compared between the two groups. | 24 hours | |
| Other | Changes of the function of dynamic cerebral autoregulation | The function of patients' dynamic cerebral autoregulation are tested 3 times within 10 days from onset and compared between the two groups. | 10 days | |
| Primary | Frequency of adverse events during hospitalization | All adverse events until day-7 or discharge (whichever is earlier) | 7 days | |
| Primary | Frequency of adverse events during follow-up | Severe adverse events through day-90 after the onset of acute ischemic stroke. | 3 months | |
| Secondary | National Institute of Health stroke scale (NIHSS) at 7 days from onset or discharge | National Institute of Health stroke scale (NIHSS) at 7 days from onset or discharge. Ranged from 0 to 42, a low value represents a better outcome. | 7 days | |
| Secondary | Proportion of patients with Modified Rankin Scale (mRS) Score 0-2 | Proportion of patients with Modified Rankin Scale (mRS) Score 0-2. Ranged from 0 to 6, a low value represents a better outcome. | 3 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
| Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
| Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
| Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
| Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
| Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
| Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
| Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
| Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
| Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
| Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
| Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
| Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
| Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
| Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
| Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
| Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
| Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |